Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis

[1]  E. Surkova,et al.  The Role of Assay of Free Immunoglobulin Light Chains in the Diagnosis of the Onset of Multiple Sclerosis , 2018, Neuroscience and Behavioral Physiology.

[2]  D. MacManus,et al.  Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study , 2018, Annals of clinical and translational neurology.

[3]  T. Yokota,et al.  Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity , 2017, Journal of the Neurological Sciences.

[4]  C. Enzinger,et al.  Prognostic value of free light chains lambda and kappa in early multiple sclerosis , 2017, Multiple sclerosis.

[5]  D. Centonze,et al.  KFLC Index utility in multiple sclerosis diagnosis: Further confirmation , 2017, Journal of Neuroimmunology.

[6]  M. Ermani,et al.  BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset , 2017, Journal of Neuroinflammation.

[7]  H. Reiber.  Knowledge-base for interpretation of cerebrospinal fluid data patterns. Essentials in neurology and psychiatry. , 2016, Arquivos de neuro-psiquiatria.

[8]  E. Surkova,et al.  Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis , 2015, PloS one.

[9]  K. Fujihara,et al.  Importance of the quotient of albumin, quotient of immunoglobulin G and Reibergram in inflammatory neurological disorders with disease‐specific patterns of blood–brain barrier permeability , 2015 .

[10]  S. Pluchino,et al.  The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis , 2015, Progress in Neurobiology.

[11]  Eric Westman,et al.  Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy , 2014, Journal of Neuroimmunology.

[12]  A. Bar-Or,et al.  Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro , 2012, Journal of Neuroimmunology.

[13]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[14]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[15]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[16]  David H. Miller,et al.  Gray matter atrophy is related to long‐term disability in multiple sclerosis , 2008, Annals of neurology.

[17]  Bruce D. Trapp,et al.  Pathogenesis of axonal and neuronal damage in multiple sclerosis , 2007, Neurology.

[18]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[19]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.